The FDA has approved a new subcutaneous formulation of Leqembi, Eisai and Biogen’s Alzheimer's treatment, enhancing administration options for patients suffering from early-stage disease. This approval represents a step forward in the companies’ strategy to compete with oral and intravenous therapies, potentially improving patient compliance and expanding market reach. The new formulation may facilitate broader adoption of amyloid-targeting strategies in dementia care.